News | Sudden Cardiac Arrest | July 02, 2019

Wearable Defibrillator Offers a Bridge Therapy

Zoll LifeVest buys time for assessment

The Zoll Lifevest Wearable External Defibrillator Offers a Bridge Therapy and buys time for physicians to determine if an implantable defibrillator is needed.

For patients at risk for sudden cardiac arrest (SCA) who are being evaluated for a permanent implantable cardioverter defibrillator (ICD), Zoll offers the LifeVest wearable defibrillator (WCD) as a temporary solution. It allows a physician more time to assess a patient’s long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear under a patient’s clothing, allowing them to return to their daily activities while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a rapid life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. This device continuously monitors the patient’s heart with dry, non-adhesive sensing electrodes to detect life-threatening abnormal heart rhythms. If a rapid life-threatening heart rhythm (VT or VF) is detected, the device alerts bystanders and delivers a treatment shock to restore normal heart rhythm. The entire event, from detecting a life-threatening arrhythmia to automatically delivering a treatment shock, usually occurs in less than a minute.

The LifeVest is used for a range of patient conditions or situations, including following a heart attack and before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

Zoll intregrates this device with the LifeVest Network online patient data management system. It allows clinicians to monitor the patient using downloaded data from a patient’s LifeVest. Clinicians can customize events that generate an alert, or to be notified for a number of events, such as detected arrhythmias, treatments, patient-recorded electrocardiograms (ECGs) and patient use.

 

Other LifeVest Related Content:

Sudden Cardiac Arrest Patient Walks to Ambulance Thanks to Wearable Defibrillator

VIDEO: Demonstration of the LifeVest Wearable Defibrillator System

Diving Deeper Into the Results of the VEST Trial Using Wearable Defibrillators

Wearable Cardioverter Defibrillators Prove Safe for Pediatric Patients

New Technology and Market Challenges Facing Implantable Cardioverter Defibrillators

 

Related Content

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Overlay Init